|
Cell Signaling Technology, Inc. (CST) is a private company that develops and produces antibodies, ELISA kits, ChIP kits, proteomic kits, and other related regents used to study the cell signaling pathways that impact human health. CST maintains an in-house research program, particularly in the area of cancer research, and has published scientific papers in many peer-reviewed journals. ==History== Cell Signaling Technology, Inc. (CST) was founded in 1999 by scientists in the Cell Signaling group at New England Biolabs (NEB).〔(A lab with a view: New research space reflects company's open, research-driven philosophy )〕 Originally housed in the Cummings Center (Beverly, Massachusetts), CST moved to its current United States headquarters located at the former King’s Grant Inn (Danvers, Massachusetts) in late 2005.〔〔(King's Grant Inn goes from hotel to biotech HQ )〕 Following extensive renovation,〔(NEW Room At The Inn )〕 the U.S. Green Building Council has certified the current headquarters as a LEED (Leadership in Energy and Environmental Design) certified facility in 2007.〔(Public buildings take the 'LEED' in New England )〕 In 2008 and 2009, CST expanded its overseas operations, establishing subsidiary offices in the People’s Republic of China, Japan, and the Netherlands.〔(Cell Signaling Technology opens unit in Japan )〕〔(Cell Signaling Technology buys Dutch distributor )〕 In 2013, CST moved its production group into an ISO9001 certified facility in Beverly, Massachusetts. The company has the capabilities to manufacture cGMP-grade antibodies. Cell Signaling Technology, Inc. (CST) was named as one of the “Top 100 Places to Work” in a 2009-2013 survey published by the Boston Globe.〔(Globe Top 100 Places to Work )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Cell Signaling Technology」の詳細全文を読む スポンサード リンク
|